Sevelamer carbonate | CAS# 845273-93-0

MedKoo Cat#: 333051 | Name: Sevelamer carbonate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sevelamer carbonate is a polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease. Sevelamer carbonate is an anion exchange resin, with the same polymeric structure as sevelamer hydrochloride, in which carbonate replaces chloride as the counterion. While the counterions differ for the two salts, the polymer itself, the active moiety involved in phosphate binding, is the same. Sevelamer carbonate is known chemically as poly(allylamine-co-N,N'-diallyl-1,3diamino-2-hydroxypropane) carbonate salt. Sevelamer carbonate is hygroscopic, but insoluble in water.

Chemical Structure

Sevelamer carbonate

CAS# 845273-93-0

Theoretical Analysis

MedKoo Cat#: 333051

Name: Sevelamer carbonate

CAS#: 845273-93-0

Chemical Formula:

Exact Mass: 0.0000

Molecular Weight: 0.00

Elemental Analysis:

Price and Availability

Size	Price	Availability
500g	USD 2,450.00	2 Weeks
1kg	USD 3,250.00	2 Weeks
2kg	USD 5,650.00	2 Weeks
5kg	USD 7,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GT335-012; GT-335-012; GT 335-012; GT335012; GT-335012; GT 335012; Sevelamer carbonate; Renvela;

IUPAC/Chemical Name

poly(allylamine-co-N,N'-diallyl-1,3diamino-2-hydroxypropane) carbonate salt

InChi Key

InChi Code

SMILES Code

Appearance

Solid powder

Purity

N/A ( ref to CoA).

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gaspar RS, Silva-Lima B, Magro F, Alcobia A, da Costa FL, Feio J. Non- biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision. Front Med (Lausanne). 2020 Nov 23;7:590527. doi: 10.3389/fmed.2020.590527. PMID: 33330550; PMCID: PMC7719831. 2: Junaid Z, Patel J. Cinacalcet. 2020 Dec 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 32491590. 3: King AJ, Kohler J, Fung C, Jiang Z, Quach A, Kumaraswamy P, Chertow GM, Rosenbaum DP. Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. Am J Physiol Renal Physiol. 2021 Jan 1;320(1):F133-F144. doi: 10.1152/ajprenal.00137.2020. Epub 2020 Dec 7. PMID: 33283643. 4: Kim T, de Oliveira Silva Lautenschlager S, Ma Q, Eller K, Pollheimer MJ, Lazarin-Bidóia D, Nakamura CV, Anders HJ, Steiger S. Drug Crystal-Related Gastrointestinal Complications Involve Crystal-Induced Release of Neutrophil and Monocyte Extracellular Traps. Cells. 2020 Nov 15;9(11):2481. doi: 10.3390/cells9112481. PMID: 33203124; PMCID: PMC7697008. 5: Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, Aghi A, Locatelli F, Cunningham J, Salam S, Zaninotto M, Ravera M, Russo D, Mereu MC, Giannini S, Brandi ML, Ferrari S, Sella S, Egan CG, Bellasi A, Di Lullo L, Tripepi G, Nickolas T. Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. J Bone Miner Res. 2020 Nov 14. doi: 10.1002/jbmr.4214. Epub ahead of print. PMID: 33188702. 6: Hill Gallant KM, Stremke ER, Trevino L, Moorthi RN, Doshi S, Wastney ME, Hisada N, Sato J, Ogita Y, Fujii N, Matsuda Y, Kake T, Moe SM. EOS789, a broad- spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a Phase 1b randomized cross-over trial in hemodialysis patients. Kidney Int. 2020 Oct 30:S0085-2538(20)31246-1. doi: 10.1016/j.kint.2020.09.035. Epub ahead of print. PMID: 33137340. 7: Spilios M, Altshuler J, Radparvar S. Safety and feasibility of crushing sevelamer tablets for enteral feeding tube administration. J Clin Pharm Ther. 2020 Oct 10. doi: 10.1111/jcpt.13290. Epub ahead of print. PMID: 33037822. 8: Elkattawy S, Alyacoub R, Ayad S, Pandya M, Eckman A. A Novel Case of Hypoparathyroidism Secondary to SARS-CoV-2 Infection. Cureus. 2020 Aug 28;12(8):e10097. doi: 10.7759/cureus.10097. PMID: 33005518; PMCID: PMC7522187. 9: Cernaro V, Calimeri S, Laudani A, Santoro D. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. Ther Clin Risk Manag. 2020 Sep 15;16:871-880. doi: 10.2147/TCRM.S196805. PMID: 32982259; PMCID: PMC7501956. 10: Smith ER, Pan FFM, Hewitson TD, Toussaint ND, Holt SG. Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial. Kidney Int Rep. 2020 Jun 29;5(9):1432-1447. doi: 10.1016/j.ekir.2020.06.014. PMID: 32954068; PMCID: PMC7486191. 11: Najim MS, Ali R, Awad M, Omer A. Pseudohypoparathyroidism presenting with seizures: a case report and literature review. Intractable Rare Dis Res. 2020 Aug;9(3):166-170. doi: 10.5582/irdr.2020.03014. PMID: 32844075; PMCID: PMC7441037. 12: Inayat F, Bokhari SRA, Almas T, Rosen RM. Drug Interaction Between Sevelamer and Levetiracetam: The First Clinical Experience. Am J Ther. 2020 Aug 14. doi: 10.1097/MJT.0000000000001241. Epub ahead of print. PMID: 32826399. 13: Wang SV, Kulldorff M, Poor S, Rice DS, Banks A, Li N, Lii J, Gagne JJ. Screening Medications for Association with Progression to Wet Age-Related Macular Degeneration. Ophthalmology. 2020 Aug 7:S0161-6420(20)30752-1. doi: 10.1016/j.ophtha.2020.08.004. Epub ahead of print. PMID: 32777229. 14: Lai T, Frugoli A, Barrows B, Salehpour M. Sevelamer Carbonate Crystal- Induced Colitis. Case Rep Gastrointest Med. 2020 Jul 23;2020:4646732. doi: 10.1155/2020/4646732. PMID: 32774946; PMCID: PMC7396044. 15: Scialla JJ, Kendrick J, Uribarri J, Kovesdy CP, Gutiérrez OM, Jimenez EY, Kramer HJ. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective. Am J Kidney Dis. 2021 Jan;77(1):132-141. doi: 10.1053/j.ajkd.2020.05.025. Epub 2020 Aug 6. PMID: 32771650. 16: Enoki Y, Suzuki N, Ito M, Uchiyama E, Kishi N, Ito C, Kitahiro Y, Sakamoto K, Taguchi K, Yokoyama Y, Kizu J, Matsumoto K. Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation. J Pharm Pharmacol. 2020 Oct;72(10):1361-1369. doi: 10.1111/jphp.13330. Epub 2020 Jul 13. PMID: 32657432. 17: Lambert O, Couchoud C, Metzger M, Choukroun G, Jacquelinet C, Mercadal L. Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry. PLoS One. 2020 Jul 6;15(7):e0235135. doi: 10.1371/journal.pone.0235135. PMID: 32628733; PMCID: PMC7337343. 18: Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020;144(9):428-439. doi: 10.1159/000507258. Epub 2020 Jun 25. PMID: 32585670; PMCID: PMC7592954. 19: Tsuji Y, Kaji K, Kitade M, Kaya D, Kitagawa K, Ozutsumi T, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Moriya K, Akahane T, Yoshiji H. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. Microorganisms. 2020 Jun 19;8(6):925. doi: 10.3390/microorganisms8060925. PMID: 32575352; PMCID: PMC7357162. 20: Dai L, Meijers BK, Bammens B, de Loor H, Schurgers LJ, Qureshi AR, Stenvinkel P, Evenepoel P. Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction? Toxins (Basel). 2020 May 27;12(6):351. doi: 10.3390/toxins12060351. PMID: 32471179; PMCID: PMC7354623.